抗-HBc定量的临床意义与应用

尹雪如; 佘格欣; 侯金林; 樊蓉

doi:10.3969/j.issn.1001-5256.2019.10.005

抗-HBc定量的临床意义与应用

DOI: 10.3969/j.issn.1001-5256.2019.10.005

南方医科大学南方医院肝病中心和感染内科

详细信息

中图分类号: R512.62
计量
- 文章访问数: 1589
- HTML全文浏览量: 48
- PDF下载量: 499
- 被引次数: 0
出版历程
- 收稿日期: 2019-08-09
- 出版日期: 2019-10-20

Clinical significance and application of quantification of hepatitis B core antibody

Hepatology Unit and Department of Infectious Diseases,Nanfang Hospital,Southern Medical University

摘要

摘要: HBV感染是全球重要的公共卫生问题。抗-HBc是人体感染HBV后产生的血清免疫学标志物之一。过去有研究表明,HBeAg阳性孕妇血清中低水平抗-HBc与婴儿免疫预防失败相关。此外,抗-HBc是与肝脏炎症活动及治疗效果相关的重要免疫学指标,可用于评估肝脏炎症、预测抗病毒疗效以及停药后持续应答。抗-HBc定量的临床应用,为乙型肝炎患者的个体化治疗开拓了新的方向。
- 乙型肝炎病毒 /
- 乙型肝炎抗体 /
- 传染性疾病传播,垂直
Abstract: Hepatitis B virus(HBV) infection is a global public health problem. Hepatitis B core antibody(anti-HBc) is one of the serum immunological markers in human body after HBV infection. Previous studies have shown that the low serum level of anti-HBc in HBeAg-positive mothers are associated with immunoprophylaxis failure in infants. In addition,anti-HBc is an important biomarker associated with liver inflammatory activity and therapeutic outcome and can be used to evaluate liver inflammation and predict the efficacy of antiviral therapy and sustained response after drug withdrawal. Anti-HBc quantification provides a new direction for individualized treatment of hepatitis B patients.
- hepatitis B virus /
- hepatitis B antibodies /
- infectious disease transmission,vertical

HTML全文

参考文献(21)

[1] Polaris Observatory Collaborators. Global prevalence,treatment,and preventionof hepatitis B virus infection in 2016:A modelling study[J]. Lancet Gastroenterol Hepatol,2018,3(6):383-403.

[2] SONG LW,LIU PG,LIU CJ,et al. Quantitative hepatitis B coreantibody levels in the natural history of hepatitis B virus infection[J]. Clin Microbiol Infect,2015,21(2):197-203.

[3] XU JH,SONG LW,LI N,et al. Baseline hepatitis B core antibody predicts treatment response in chronic hepatitis B patients receiving long—term entecavir[J]. J Viral Hepat,2017,24(2):148-154.

[4] VISVANATHAN K,DUSHEIKO G,GILES M,et al. Managing HBV in pregnancy. Prevention,prophylaxis,treatment and follow-up:Position paper produced by Australian,UK and New Zealand key opinion leaders[J]. Gut,2016,65(2):340-350.

[5] CHEN HL,LIN LH,HU FC,et al. Effects of maternal screening and universal immunization to prevent mother-to-infant transmission of HBV[J]. Gastroenterology,2012,142(4):773-781.

[6] ROUSHAN MRH,SAEDI F,SOLEIMANI S,et al. Changes in the anti-HBc profile of infants born to HBV infected mothers from Iran[J]. Vaccine,2016,34(38):4475-4477.

[7] ALEXANDER GJ,EDDLESTON AL. Does maternal antibody to core antigen prevent recognition of transplacental transmission of hepatitis B virus infection?[J]Lancet,1986,1(8476):296-297.

[8] THOMAS HC,LEVER AM. Has immunology become important to the hepatologist?[J] Progr Liver Dis,1986,8:179-189.

[9] CHANG MH,HSU HY,HUANG LM,et al. The role of transplacental hepatitis B core antibody in the mother-to-infant transmission of hepatitis B virus[J]. J Hepatol,1996,24(6):674-679.

[10] LEE JH,PAGLIERONIC TG,HOLLAND PV,et al. Chronic hepatitis B virus infection in an HBc antibody-nonreactive blood donor:variant virus or defective immune response?[J]. Hepatology,1992,16(1):24-30.

[11] Chinese Society of Hepatology and Chinese Society of Infectious Diseases,Chinese Medical Association. The guideline of prevention and treatment for chronic hepatitis B:A 2015 update[J]. J Clin Hepatol,2015,31(12):1941-1960.(in Chinese)中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南(2015年更新版)[J].临床肝胆病杂志,2015,31(12):1941-1960.

[12] ZHOU J,SONG L,ZHAO H,et al. Serum hepatitis B core antibody as a biomarker of hepatic inflammation in chronic hepatitis B patients with normal alanine aminotransferase[J]. Sci Rep,2017,7(1):2747.

[13] FAN R,SUN J,YUAN Q,et al. Baseline quantitative hepatitis B core antibody titre alone strongly predicts HBe Ag seroconversion across chronic hepatitis B patients treated with peginterferon or nucleos(t)ide analogues[J]. Gut,2016,65(2):313-320.

[14] CHI H,LI Z,HANSEN BE,et al. Serum level of antibodies against hepatitis B core protein is associated with clinical relapse after discontinuation of nucleos(t)ide analogue therapy[J]. Clin Gastroenterol Hepatol,2019,17(1):182-191. e1.

[15] KUMAR M,SARIN SK,HISSAR S,et al. Virologic and histologic features of chronic hepatitis B virus-infected asymptomatic patients with persistently normal ALT[J]. Gastroenterology,2008,134(5):1376-1384.

[16] LI J,ZHANG TY,SONG LW,et al. Role of quantitative hepatitis B core antibody levels in predicting significant liver inflammation in chronic hepatitis B patients with normal or near-normal alanine aminotransferase levels[J]. Hepatol Res,2018,48(3):e133-e145.

[17] WU Z,DONG X,WANG G,et al. Clinical noninvasive markers for antiviral therapy decision in chronic hepatitis B with alanine aminotransferase less than two times upper limit of normal[J].J Viral Hepat,2019,26(2):287-296.

[18] YUAN Q,SONG LW,LIU CJ,et al. Quantitative hepatitis B core antibody level may help predict treatment response in chronic hepatitis B patients[J]. Gut,2013,62(1):182-184.

[19] XU JH,SONG LW,LI N,et al. Baseline hepatitis B core antibody predicts treatment response in chronic hepatitis B patients receiving long-term entecavir[J]. J Viral Hepat,2017,24(2):148-154.

[20] CAI S,LI Z,YU T,et al. Serum hepatitis B core antibody levels predict HBe Ag seroconversion in chronic hepatitis B patients with high viral load treated with nucleos(t)ide analogs[J]. Infect Drug Resist,2018,11:469-477.

[21] TSENG CH,HSU YC,CHANG CY,et al. Quantification of serum hepatitis B core antibody to predict off-entecavir relapse in patients with chronic hepatitis B[J]. J Formos Med Assoc,2018,117(10):915-921.

施引文献

资源附件(0)

访问统计